Articles by John

I have been building forums to promote the life sciences community for over 10 years. I enjoy exploring the issues, individuals and companies impacting the life/med/health tech community, and celebrating the innovators, entrepreneurs and policy makers who are actively working to build the community.


dna-sequencing-banner
0

Is Amgen The Next Big Split?

First Abbott split and created AbbVie, then Baxter with Baxalta, is Amgen up next? I am placing best the new spin off will be called Pmgen. Hedge fund manager Daniel Loeb is lending his voice to the chorus of investors who believe Amgen ($AMGN) would do better as two companies. And his firm, Third Point,…

Horizon___Widescreen_Wallpaper_by_hameed
0

Philips Looking to HealthTech to Bolster Bottom Line

Philips ($PHG) shed as much as 4% in early trading as continued manufacturing problems and intellectual property litigation as well as weakness in Russia and China weighed on investor confidence after it reported third-quarter results. The conglomerate had a net loss of €103 million ($132 million) on sales of €5.5 billion in the third quarter,…

wpid-Photo-20140711095706.jpg
0

FDA Extends Exclusivity for Certain Combo-Meds

What’s two extra years of exclusivity worth? Enough to spark a legal fight. The FDA posted new guidance on its website Friday, awarding certain combo meds 5 years of exclusivity compared with the previous three. Drugmakers had lobbied for the change, but the timing–and the wording–are bound to be controversial.

baxter_split_jpeg_04fbd_i-DTI-03272014
0

Gambro Acquisition Fuels Baxter’s Growth Before Split

The acquisition of dialysis company Gambro last September continues to fuel Baxter International’s ($BAX) sales growth as it preps to spin out its biopharma division in 2015. But despite some stop-gap measures, it’s not likely that Baxter will actually be able to meet the demand for its dialysis products until additional manufacturing capacity opens up in 2016.

Copyright © 2014 WhiteCityNews, All rights reserved.